Retatrutide vs Semaglutide: Triple Agonism and the Evidence
Separate receptor biology, published obesity trials, and new company-reported diabetes results in this comparison of retatrutide and semaglutide research.
| Retatrutide targets | GIP, GLP-1, and glucagon receptors |
|---|---|
| Semaglutide target | GLP-1 receptor |
| Direct comparison | TRANSCEND-T2D-2, company topline results |
| Direct-trial population | Adults with type 2 diabetes |
| Retatrutide status | Investigational as of November 5, 2026 |
| Hero product | Hero RT |
Retatrutide vs semaglutide compares two different approaches to peptide design. Semaglutide activates GLP-1 receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors. The useful research question is what that broader profile changes, and how confidently a study can explain the change.
The evidence now includes an important update. Lilly announced a direct comparison on October 28, 2026. Those results belong beside the published studies, with a clear label showing that they are company-reported topline findings from adults with type 2 diabetes (Eli Lilly, 2026).
Origin story: adding a third receptor
Semaglutide’s discovery program focused on a GLP-1 analog with extended exposure. Retatrutide’s discovery program, under the name LY3437943, explored a single molecule able to activate three receptors. The papers describe different molecular solutions to metabolic research questions (Lau et al., 2015; Coskun et al., 2022).
That history matters when interpreting comparisons. Retatrutide is not semaglutide with two separate ingredients added. It is its own engineered molecule. A difference in outcome cannot automatically be assigned to one added receptor without experiments designed to test that explanation.
The retatrutide research guide and semaglutide research guide provide compound-specific background. This article focuses on what can be compared across the available evidence.
How retatrutide and semaglutide work
The discovery studies establish the central distinction: semaglutide is a GLP-1 receptor agonist, while retatrutide combines GIP, GLP-1, and glucagon receptor agonism. Retatrutide’s design was investigated through receptor assays, animal studies, and early human research (Lau et al., 2015; Coskun et al., 2022).
Receptor activation is only one part of the comparison. Concentration at the target, duration of exposure, and the model’s receptor expression also influence an observed response. A receptor profile provides a starting hypothesis, rather than a complete prediction of every downstream effect.
For a laboratory comparison, decide whether the aim is to measure receptor signaling or a broader metabolic response. A cell assay with one receptor can help separate direct signaling. A whole organism adds feedback and tissue interactions that need a different interpretation.
Key studies: published trials and a new direct comparison
| Evidence | Model or population | Finding or scope | Boundary |
|---|---|---|---|
| Retatrutide phase 2, 2023 | Adults with obesity without diabetes, 48 weeks | Mean weight change of −24.2% in the highest studied group, versus −2.1% with placebo | Separate placebo-controlled trial |
| Semaglutide STEP 1, 2021 | Adults with overweight or obesity without diabetes, 68 weeks | Mean weight change of −14.9%, versus −2.4% with placebo | Different study and duration |
| TRANSCEND-T2D-2, October 2026 announcement | Adults with type 2 diabetes, 80 weeks | Direct retatrutide versus Ozempic comparison | Company topline report |
The first two rows come from different trials. Their percentages cannot establish direct superiority because participants, follow-up, and study methods differed (Jastreboff et al., 2023; Wilding et al., 2021).
For TRANSCEND-T2D-2, Lilly reported mean weight reductions of 19.5% and 20.9% in the two retatrutide groups, versus 9.4% with Ozempic. Reported HbA1c reductions were 2.2 percentage points in both retatrutide groups and 1.8 points with the comparator. These were efficacy-estimand results (Eli Lilly, 2026).
The announced comparator was Ozempic 2 mg. The trial therefore does not answer every comparison involving semaglutide formulations or obesity populations. Full results were still described as intended for a future meeting and peer-reviewed publication in that announcement (Eli Lilly, 2026).
A careful evidence summary keeps three labels visible: direct or indirect comparison, diabetes or no diabetes, and published paper or topline announcement. Removing any one can make the same number sound more conclusive than its source supports.
Weak spots: what we don’t know
More receptor targets do not establish a broader safety margin. Retatrutide’s phase 2 trial reported gastrointestinal adverse events and increases in heart rate. STEP 1 also reported gastrointestinal events with semaglutide. Comparisons need tolerability data as well as efficacy endpoints (Jastreboff et al., 2023; Wilding et al., 2021).
A trial showing a difference in body weight does not by itself prove which receptor caused that difference. It also cannot demonstrate a particular tissue mechanism without the measurements needed to evaluate that mechanism.
As of November 5, 2026, retatrutide remains investigational, according to Lilly’s October announcement. FDA-approved semaglutide medicines exist, including Wegovy. That product approval does not establish approval or clinical equivalence for research vials sold under a supplier brand (Eli Lilly, 2026; FDA, 2021).
Handling retatrutide and semaglutide in the lab
Start with confirmed identity and lot-specific documentation. The material used in a publication and a commercial research lot should not be treated as interchangeable merely because their names match. Record the sequence or identifier and the analytical evidence available.
For a concentration example, bring a nominal 5 mg research vial to a final volume of 2 mL. The result is 2.5 mg/mL, or 2,500 mcg/mL. A 0.10 mL analytical aliquot contains 250 mcg. If the vial instead contains 10 mg at the same final volume, concentration doubles.
On a U-100 scale, 0.10 mL corresponds to 10 volume units. That conversion does not define a biological exposure or an assay’s required concentration. Choose the working concentration from the experimental design and use suitable laboratory measuring equipment.
The reconstitution guide and calculator help check mass and volume. Solvent choice and storage still need material-specific support. Arithmetic cannot supply an expiry date or confirm that a prepared solution remains active.
Retatrutide vs semaglutide FAQ
Has a direct comparison been reported?
Yes. Lilly announced TRANSCEND-T2D-2 topline findings on October 28, 2026, in adults with type 2 diabetes (Eli Lilly, 2026).
Can separate obesity trial percentages prove superiority?
No. Cross-trial comparisons generate questions, but different populations and designs prevent a clean direct conclusion.
Does triple agonism identify the mechanism behind every outcome?
No. Assigning an effect to a particular receptor requires experiments that can separate the receptor contributions.
What is Hero RT?
Hero RT is Hero Peptides’ retatrutide research material, listed in 5 mg and 10 mg vial sizes. It is distinct from investigational medicine supplied within clinical trials.
References
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. Source.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. Source.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Source.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Source.
- Eli Lilly and Company. Lilly’s retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial. Company topline announcement, October 28, 2026. Source.
- U.S. Food and Drug Administration. Wegovy (semaglutide), NDA 215256, approval review. 2021. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.